Compare FIEE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | VERU |
|---|---|---|
| Founded | 1977 | 1971 |
| Country | Hong Kong | United States |
| Employees | 30 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 44.0M |
| IPO Year | 2010 | 1996 |
| Metric | FIEE | VERU |
|---|---|---|
| Price | $3.88 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 16.2K | ★ 187.4K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.46 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $47,988,549.00 | $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.24 | ★ N/A |
| Revenue Growth | ★ 27.58 | N/A |
| 52 Week Low | $1.50 | $2.05 |
| 52 Week High | $10.59 | $7.33 |
| Indicator | FIEE | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 50.02 |
| Support Level | $3.74 | $2.50 |
| Resistance Level | $3.97 | $2.85 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 30.00 | 40.22 |
FiEE Inc is a digital service provider focused on integrating artificial intelligence (AI) and data analytics into content creation, digital authentication, and brand management. Its business model leverages a cloud-based SaaS platform designed to support clients in developing, managing, and optimizing their digital presence across platforms, including customized graphics and posts, short videos, and editorial calendars aligned with brand goals. Additionally, it offers comprehensive software development and maintenance services, delivering custom software solutions from system design and development to deployment and post-launch maintenance. It services consist of three core areas: digital content and MCN services, software development services, and digital authentication services.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.